T
Ten63 Therapeutics
Proprietary drug discovery engine BEYOND, combining physics and AI in hyper-efficient search algorithms, to design potent chemistry against hard targets and exceed conventional therapeutic research…
About Ten63 Therapeutics
Ten63 operates in the biotechnology sector, focusing on drug discovery through its proprietary AI-driven platform, BEYOND. The company targets previously undruggable chemical spaces, aiming to develop new therapeutics. Ten63 serves pharmaceutical companies and research institutions, providing them with innovative solutions to complex medical challenges. The business model revolves around leveraging advanced AI and physical models to identify potential drug candidates, which are then validated experimentally. Revenue is generated through partnerships, licensing agreements, and milestone payments from successful drug discoveries. The market for Ten63's services includes global pharmaceutical companies and biotech firms seeking cutting-edge drug discovery technologies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 34
- Open positions
- None listed
- Dealroom signal
- 86.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Core AI, Spinout, Biotech and Pharma, AI Applications, DT and LS, science-based
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Feb 2026 | $0 | — | Bill & Melinda Gates Foundation · Chugai Venture Fund | ↗ |
| SERIES A✓Equity / VC | May 2023 | $16M | $64M | Morpheus Ventures · Alexandria Venture Investments · Draper Associates · Hatteras Venture Partners | ↗ |
Growth signals
Latest recorded traffic for Ten63 Therapeutics is 1.4K monthly website visits, down 65% over the last three months. Ten63 Therapeutics's team grew 25.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Ten63 Therapeutics in the Durham ecosystem
The Ten63 Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A7 investors entered at this stage
Morpheus Ventures
Alexandria Venture Investments
Draper Associates
Hatteras Venture Partners
Sigma Group
Bill & Melinda Gates Foundation- CFChugai Venture Fund
Other known investors3 additional known investors
Duke University
Indie Bio
Duke Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ten63 Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ten63 Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










